Grimes & Company’s Filana Therapeutics FLNA Stock Holding History

Grimes & Company’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,692	Closed	-$291K	–	313
2021 Q3	$291K	Hold	4,692	–	–	0.01%	245
2021 Q2	$401K	Buy	+4,692	New	+$251K	0.02%	213

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Grimes & Company's FLNA Position: Q4 2021 in Review

Grimes & Company sold out of Filana Therapeutics (FLNA) in Q4 2021, closing a stake of 4,692 shares — an estimated $291K sold.

Grimes & Company first reported a position in FLNA in Q2 2021 and held it in 2 quarters. The position peaked at $401K in Q2 2021. 171 funds tracked by Wall St. Rank hold FLNA as of Q4 2021.

Grimes & Company reported no remaining Filana Therapeutics position as of Q4 2021 after selling out during the quarter.
Grimes & Company sold 4,692 Filana Therapeutics shares in Q4 2021, an estimated $291K.
Grimes & Company first reported a position in Filana Therapeutics in Q2 2021 and held it in 2 quarters.
Grimes & Company's Filana Therapeutics position peaked at $401K in Q2 2021.
171 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2021.

Based on Grimes & Company's 13F filing for Q4 2021, filed 1 Feb 2022.